What You Will Learn

Please join Carterra at our upcoming symposium in San Francisco, CA.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Antibody Discovery Workflows
Machine Learning and AI Approaches for Protein Engineering
Antibody Validation and Multifunctional Antibodies
Biophysical Characterization and High-Definition Epitope Binning Enabling Novel Biotherapeutics
DELs, PROTACs, and Fragment Drug Discovery

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

See Agenda Below

Companies presenting in 2025:

Agenda	Symposium co-hosted by Curia
9:45 – 10:00 AM	Arrive and Check-in
10:00 – 10:30 AM	Networking and Coffee/Tea
10:30 – 10:45 AM	Symposium Begins—Welcome
10:45 – 11:15 AM	James Fishburn, Senior Scientist, Pfizer HT-SPR Evaluation of Critical Reagent Antibodies Yields Expected and Unexpected Benefits
	Abstract: Antibody-drug conjugates (ADCs) are an important and growing class of oncologic therapeutics that have the potential for a broad therapeutic index and reduced immunogenicity in patients. These metrics are closely monitored in clinical trials using bioanalytical methods that employ critical reagents, which are frequently ADC-specific anti-idiotype (anti-ID) antibodies. At Pfizer, we utilize a Carterra LSA to evaluate our reagent candidates to ensure that there is accurate and specific detection of our ADCs. This process allows us to comprehensively understand the binding characteristics of each anti-ID, which subsequently guides our selection of the anti-ID reagents for use in the pharmacokinetic and immunogenicity assays of our experimental ADCs. This presentation details our evaluation methodology and its advantages, and shares an unexpected discovery of cooperatively binding anti-IDs that was enabled by the LSA.
11:15 – 11:45 AM	Jin Choi, PhD, Senior Scientist, Attovia Therapeutics HT-SPR and Therapeutic Attobody Discovery
	Abstract: Attobody^® is a biparatopic VHH and usually gives 100-1000-fold affinity boost compared to its comprising VHHs. ATTO-1310 is our first Attobody^® targeting IL31 with double-digit pM KD. The Atto-1310 was discovered through library screening on a yeast display platform and HT-SPR using Carterra LSA. The ATTO-1310 shows excellent developability, potent suppression of IL31-mediated downstream signaling in vitro and anti-pruritic activity in mice and NHP. ATTO-1310 also shows good pharmacokinetic (PK) profile in NHP.
11:45 AM – 12:15 PM	Karanbir Pahil, PhD, Investigator, GSK High-Throughput SPR in DNA-Encoded Library Screening and Hit Validation
	Abstract: DNA-encoded libraries (DELs) enable drug discovery chemists to identify thousands of hits from screening campaigns using billions of molecules, producing a vast array of small molecule structure-activity relationship data and potentially interesting chemical matter that needs to be triaged efficiently. DELs are made combinatorically, with every library member being assigned a unique DNA barcode, and every step of chemistry being compatible with the presence of DNA. Here, we show how we leverage the facility of resynthesizing DEL screening hits with DNA tags and the Carterra LSA^® platform to enable high throughput binding assays.
12:15 - 1:15 PM	Lunch and Networking
1:15 – 1:45 PM	Yadong Yu, PhD, Senior Research Scientist III, Curia VHH Antibody Discovery for huCD200R1
	Abstract: Nanobodies are a growing modality in antibody therapeutics, with FDA-approved treatments driving demand for VHH discovery. Their small size and typically longer CDR3 enables targeting challenging epitopes in solid tumors, overcoming limitations of larger antibodies. Here we used single B cell antibody discovery to rapidly identify a diverse set of potent, high affinity, neutralizing VHH from immunized llamas against CD200R1, an emerging therapeutic immune checkpoint target.
1:45 – 2:15 PM	Jack Hu, PhD, Director of Antibody Engineering, Aureka Biotechnologies Rapid Design of Dual-specific Antibody Therapeutics Using AI and High-Throughput Biology
	Abstract: Aureka Biotechnologies develops life-saving antibody therapeutics at scale, powered by generative AI and high-throughput biology platform. With multiple biopharma partners, Aureka's platform has been validated to discover differentiated antibodies that would otherwise be difficult for traditional methods. Our high-value applications include single paratope antibodies binding multiple targets, receptor agonists, pH-dependent recycling antibodies, internalizing biparatopic antibodies, and epitope-specific de novo design. This presentation will introduce our single-paratope, dual-binding IgG antibody pipeline, enabled by iterative AI and data workflow including validation using Carterra’s high-throughput SPR. Dual specific IgG offers advantages over bispecific antibodies in developability and manufacturability and can enable novel MOA.
2:15 – 2:45 PM	Dan Bedinger, PhD, Sr. Manager Field Application Science, Carterra Applications from mAbs to Fragment Screening: How Carterra LSA, LSA^XT and Ultra HT-SPR Platforms Enable Highly Parallel Analysis Advancing All Drug Discovery Modalities
	Abstract: Carterra’s HT-SPR technology platforms have set the bar for throughput and scalability for biologics discovery and now extend to small molecule and fragment screening. The Carterra Ultra enables a transformative approach to library screening, highly parallel analysis, where many targets can be screened simultaneously against a library. Why run single campaigns when you can screen your entire target backlog simultaneously? This presentation will highlight three interesting application examples: the detailed kinetic characterization of human Fab fragments directly from bacterial extracts, the profiling of binding of TCRs to arrays of immobilized pMHCs, and fragment library screening.
2:45 – 3:15 PM	Coffee and Networking
3:15 PM	Symposium Ends

What You Will Learn

Register Here

Agenda